11-Aug-2025      14:36

Ipca Labs Q1 PAT climbs 21% YoY to Rs 233 cr

Revenue from operations jumped 10.33% year on year to Rs 2,308.85 crore in the quarter ended 30 June 2025.

Profit before tax (PBT) increased 13.81% to Rs 330.51 crore in Q1 FY25, compared with Rs 290.39 crore in Q1 FY25.

EBITDA stood at Rs 424.58 crore in Q1 FY26, registering the growth of 10%, compared with Rs 387.49 crore in Q1 FY25. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) stood at 18.39% in Q1 FY26 as against at 18.52% in Q1 FY25.

During the quarter, total formulations were at Rs 1,410.62 crore, up 11% YoY. Domestic business stood at Rs 961.01 crore (up 10% YoY).

Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.

Shares of Ipca Laboratories fell 3.62% to Rs 1,334.40 on the BSE.

Powered by Capital Market - Live News

News source: Capital Market - Live News